drugset / Trial / NCT01602029

Randomized Double Blind Placebo Control Study in Patients with Schizophrenia

NCT01602029

RandomizedFactorialDouble-blindTreatment

Summary

Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either and arguably no effect on primary negative symptoms. Social dysfunction has major economic consequences in both the developed and developing world. There is evidence that anti-inflammatory treatment may have beneficial effects in patients with schizophrenia.

Timeline

Start
2010-08
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ondansetron Other / unclassified 8 mg
Comparator Simvastatin Small molecule 40 mg